MA27671A1 - Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement - Google Patents

Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement

Info

Publication number
MA27671A1
MA27671A1 MA28526A MA28526A MA27671A1 MA 27671 A1 MA27671 A1 MA 27671A1 MA 28526 A MA28526 A MA 28526A MA 28526 A MA28526 A MA 28526A MA 27671 A1 MA27671 A1 MA 27671A1
Authority
MA
Morocco
Prior art keywords
rapamycin
treatment
combination
pharmaceutical compositions
derivative
Prior art date
Application number
MA28526A
Other languages
English (en)
Inventor
Henrietta Moore
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33032928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27671(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0306070A external-priority patent/GB0306070D0/en
Priority claimed from GB0306868A external-priority patent/GB0306868D0/en
Priority claimed from GB0319226A external-priority patent/GB0319226D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27671A1 publication Critical patent/MA27671A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques comprenant en combinaison la rapamycine ou un dérivé de rapamycine et un composé de formule (I), ces compositions pouvant être utiles dans le traitement de maladies inflammatoires et de maladies induites immunologiquement, telles que les maladies auto-immunes.
MA28526A 2003-03-17 2005-09-30 Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement MA27671A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0306070A GB0306070D0 (en) 2003-03-17 2003-03-17 Organic compounds
GB0306868A GB0306868D0 (en) 2003-03-25 2003-03-25 Organic compounds
GB0319226A GB0319226D0 (en) 2003-08-15 2003-08-15 Organic compounds

Publications (1)

Publication Number Publication Date
MA27671A1 true MA27671A1 (fr) 2005-12-01

Family

ID=33032928

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28526A MA27671A1 (fr) 2003-03-17 2005-09-30 Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement

Country Status (25)

Country Link
US (1) US20060154952A1 (fr)
EP (1) EP1608368B8 (fr)
JP (1) JP2006515017A (fr)
KR (1) KR100855140B1 (fr)
AR (1) AR043504A1 (fr)
AT (1) ATE409479T1 (fr)
AU (1) AU2004222563B2 (fr)
BR (1) BRPI0408423A (fr)
CA (2) CA2517671A1 (fr)
CL (1) CL2004000535A1 (fr)
DE (1) DE602004016830D1 (fr)
EC (1) ECSP056006A (fr)
ES (1) ES2315648T3 (fr)
HR (1) HRP20050800A2 (fr)
IS (1) IS8028A (fr)
MA (1) MA27671A1 (fr)
MX (1) MXPA05009934A (fr)
MY (1) MY137868A (fr)
NO (1) NO20054778L (fr)
PE (1) PE20050313A1 (fr)
PL (1) PL1608368T3 (fr)
PT (1) PT1608368E (fr)
TN (1) TNSN05197A1 (fr)
TW (2) TW200503703A (fr)
WO (1) WO2004082681A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070070184A (ko) * 2004-10-28 2007-07-03 와이어쓰 자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도
CA2719134C (fr) * 2008-03-21 2015-06-30 The University Of Chicago Traitement avec des antagonistes des opioides et des inhibiteurs mtor
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2010206840B2 (en) 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
RU2449806C1 (ru) * 2010-11-30 2012-05-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения красного плоского лишая слизистой оболочки полости рта
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
RU2732908C2 (ru) 2014-10-07 2020-09-24 ЭйАй ТЕРАПЬЮТИКС, ИНК. Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
CR20170510A (es) 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
EP3565520B1 (fr) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
PH12022550326A1 (en) 2019-08-13 2023-03-13 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
PT956034E (pt) * 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
BR0209474A (pt) * 2001-05-09 2006-02-07 Novartis Ag Métodos para imunomodulação seletiva
BR0306858A (pt) * 2002-01-10 2004-11-03 Novartis Ag Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma
EP1501565B1 (fr) * 2002-05-09 2006-11-02 Hemoteq GmbH Composes et procedes pour recouvrir de fa on hemocompatible des surfaces

Also Published As

Publication number Publication date
AU2004222563A1 (en) 2004-09-30
PE20050313A1 (es) 2005-06-14
IS8028A (is) 2005-09-15
CA2633287A1 (fr) 2004-09-30
EP1608368B1 (fr) 2008-10-01
DE602004016830D1 (de) 2008-11-13
US20060154952A1 (en) 2006-07-13
KR100855140B1 (ko) 2008-08-28
ES2315648T3 (es) 2009-04-01
MXPA05009934A (es) 2006-03-21
JP2006515017A (ja) 2006-05-18
KR20050110023A (ko) 2005-11-22
BRPI0408423A (pt) 2006-03-21
NO20054778D0 (no) 2005-10-17
ATE409479T1 (de) 2008-10-15
HRP20050800A2 (en) 2006-11-30
NO20054778L (no) 2005-12-19
ECSP056006A (es) 2006-01-27
MY137868A (en) 2009-03-31
HK1086743A1 (en) 2006-09-29
WO2004082681A1 (fr) 2004-09-30
EP1608368A1 (fr) 2005-12-28
EP1608368B8 (fr) 2009-06-10
AR043504A1 (es) 2005-08-03
TNSN05197A1 (en) 2007-06-11
CL2004000535A1 (es) 2005-01-14
TW200835484A (en) 2008-09-01
TW200503703A (en) 2005-02-01
PT1608368E (pt) 2009-01-27
WO2004082681B1 (fr) 2004-11-25
PL1608368T3 (pl) 2009-03-31
AU2004222563B2 (en) 2006-11-02
CA2517671A1 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA27671A1 (fr) Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement
ATE371645T1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
DE602004013563D1 (de) Rantagonisten
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
MY145074A (en) Thiazolidin-4-one derivatives
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
EP1605936A4 (fr) Antagonistes du recepteur cgrp d'aryl spirohydantoine
MA32231B1 (fr) Composés organiques
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
EP1641423A4 (fr) Antagonistes du recepteur du cgrp de
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
MA32931B1 (fr) Compositions antimicrobiennes
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides